RaQualia and Carna Biosciences Announce Collaborative Research Agreement on Drug Discovery Research for a Kinase

March 22, 2013 – RaQualia Pharma Inc. (RaQualia) and Carna Biosciences, Inc. (Carna Biosciences) today announced that they have entered into a collaborative research agreement. The partnership will focus on drug discovery research for a specific kinase.

As part of the collaboration, RaQualia and Carna Biosciences will jointly work to identify an innovative drug candidate, combining RaQualia’s high-throughput screening capabilities and its drug discovery expertise, and Carna Biosciences’ kinase drug discovery technologies.

Under the agreement, the two companies will equally share the results from the collaboration: the right of a new drug candidate and the proceeds from the out-licensing of the product.

*About kinase:* Kinases are enzymes that transfer a phosphate group from ATP, adenosine-5’-triphosphate, to a substrate. Kinases are well recognized as attractive drug targets since perturbation of kinase activity is linked to diseases by modulating signal cascades, including cell proliferation, differentiation, metabolism, and immune response.

*About RaQualia:* RaQualia Pharma Inc. is an innovative life science company engaging in the discovery, development and marketing of clinical and pre-clinical candidates for unmet medical needs worldwide. For additional information, please visit www.raqualia.com

*About Carna Biosciences:* Carna Biosciences is a biotechnology company leveraging deep understanding of the cell signaling processes to develop a robust pipeline of drugs for highly unmet medical needs including cancer, inflammatory diseases and neurological diseases. The company is also providing drug discovery supporting services using Carna’s proprietary kinase drug discovery technology. For additional information, please visit www.carnabio.com